Melita Sun Jung
Chief Business Officer

Ms. Jung joins Terns with more than 20 years of experience in the life sciences industry, leading corporate strategy and business development, commercial planning and execution, financings and investment management. Most recently, she served as chief business officer at Structure Therapeutics, where she was responsible for the company’s business strategy, partnering initiatives, commercial planning, corporate branding and communications. She was part of the executive team that completed Structure’s initial public offering (IPO) of approximately $185 million, the first sizeable biotech IPO of 2023. Previously, Ms. Jung served as senior vice president and head of business development at Sangamo Therapeutics, a genomic medicines company. There she led collaboration and licensing deals with a combined potential value exceeding $6 billion and upfront payments of more than $500 million from broad strategic partnerships with Pfizer, Kite (a Gilead company), Biogen and Novartis.

Her prior experiences include corporate development and commercial roles at Adamas Pharmaceuticals and Ipsen, where she led marketing strategy and contributed to multiple product launches. She started her career in biotechnology venture capital and fund management at Bay City Capital and Lombard Odier Darier Hentsch. Ms. Jung earned a B.A. in biology from the University of California, Berkeley.